UVEA-Brig was a retrospective study that evaluated the efficacy of brigatinib in previously treated ALK-positive NSCLC (1 to 6 previous therapy lines) in four different countries with a median follow-up of 16.5 months [28]. This evidence concerns the gene ALK and non-small cell lung carcinoma.